Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results

$ARWR
$GSK
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ARWR alert in real time by email

Conference Call and Webcast Today, August 7, 2023 at 4:30 p.m. ET

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m. ET to discuss the results.

Webcast and Conference Call and Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of the call.

For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIcd0f2b791a4f4cdd97a1c78e09086106. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

Selected Recent Events

  • Hosted a Research & Development Day to discuss progress towards the company's "20 in 25" goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiMTM) platform to a total of 20 clinical stage or marketed products in the year 2025. Key updates included:
    • New Phase 1 clinical data on ARO-RAGE showing a continued dose response in healthy volunteers with a single inhaled dose of 184 mg achieving mean knockdown of 90% and a maximum of 95% in bronchoalveolar lavage fluid (BALF)
    • Serum sRAGE reductions in asthma patients consistent with effects seen in healthy volunteers at the 44 mg dose, the only dose level with results currently available in asthma patient cohorts
    • TRiMTM platform for intrathecal administration for central nervous system (CNS) delivery demonstrates 90-95% dose-dependent mRNA knockdown in disease-relevant spinal cord and cortex brain regions in non-human primates
    • TRiMTM platform for adipose tissue delivery achieved up to 98% knockdown and maintained greater than 85% knockdown over 31 weeks
    • TRiMTM dimer platform for delivery to hepatocytes achieved equivalent or better knockdown of two separate target genes with longer duration than monomer mixture
  • Completed enrollment of the global PALISADE Phase 3 clinical trial evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome. The company anticipates that the primary portion of the study will be complete in the second quarter of 2024 with a data readout shortly thereafter
  • Presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3 in patients with homozygous familial hypercholesterolemia at the 91st European Atherosclerosis Society Congress showing that ARO-ANG3 achieved 44-48% mean reductions in LDL-C on top of continued standard of care
  • Presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency at the European Association for the Study of the Liver (EASL) Congress 2023
  • Filed an application to initiate a Phase 1 clinical trial of ARO-SOD1, an RNAi-based investigational medicine designed to reduce expression of superoxide dismutase 1 (SOD1) in the CNS as a potential treatment for patients with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations. ARO-SOD1 is the first therapeutic candidate designed for delivery to the CNS to enter clinical studies that leverages the TRiMTM platform
  • Filed an application to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company's investigational RNAi therapeutic being developed as a potential treatment for patients with facioscapulohumeral muscular dystrophy (FSHD). ARO-DUX4 is the first clinical candidate utilizing the TRiMTM platform to target disease associated genes in skeletal muscle
  • Earned a $30 million milestone payment from GSK (NYSE:GSK) following the start of GSK's Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNAi therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH)
  • Earned a $40 million milestone payment from Takeda (NYSE:TAK) after the first patient was dosed in the Phase 3 REDWOOD clinical study of fazirsiran

Selected Fiscal 2023 Third Quarter Financial Results

Three Months Ended June 30,

OPERATING SUMMARY

 

2023

 

 

2022

 

(unaudited)

Revenue

$

15,825

$

32,412

Operating Expenses:

 

 

 

Research and development

 

94,757

 

72,180

General and administrative expenses

 

23,771

 

 

33,141

Total Operating Expenses

 

118,528

 

105,321

Operating loss

 

(102,703)

 

 

(72,909)

Interest income

 

4,172

 

 

1,240

 

Interest expense

 

(5,158)

 

 

-

Other, net

 

306

 

(377)

 

Loss before income tax expense and noncontrolling interest

 

(103,383)

 

 

(72,046)

 

Income tax expense

 

742

 

 

-

Net loss before noncontrolling interest

 

(104,125)

 

 

(72,046)

Net loss attributable to noncontrolling interest, net of tax

 

(1,179)

 

-

Net loss attributable to Arrowhead Pharmaceuticals, Inc.

$

(102,946)

 

$

(72,046)

 

Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted

$

(0.96)

 

$

(0.68)

Weighted-average shares used in calculating - Diluted

 

107,004

 

105,753

 

FINANCIAL POSITION SUMMARY

June 30,

2023

 

September 30,

2022

 

(unaudited)

Cash, cash equivalents and restricted cash

$

105,334

$

108,005

Short-term investments

 

346,369

 

 

268,391

Long-term investments

 

42,758

 

105,872

Total cash resources (cash and investments)

 

494,461

 

 

482,268

Other assets

 

301,395

 

209,671

Total Assets

$

795,856

 

$

691,939

 

Current deferred revenue

$

16,905

 

$

74,099

Long-term deferred revenue

 

-

 

55,950

Other liabilities

 

396,966

 

 

143,551

Total Liabilities

$

413,871

$

273,600

 

 

 

 

Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity

$

364,830

$

398,520

Noncontrolling Interest

 

17,155

 

 

19,819

Total Noncontrolling Interest and Stockholders' Equity

 

381,985

 

418,339

Total Liabilities, Noncontrolling Interest and Stockholders' Equity

$

795,856

 

$

691,939

 

Shares Outstanding

 

107,102

 

 

105,960

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Get the next $ARWR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARWR
$GSK
$TAK

CompanyDatePrice TargetRatingAnalyst
2/12/2025Equal-Weight
Morgan Stanley
11/15/2024Buy → Hold
Deutsche Bank
11/12/2024$53.00 → $39.50Buy → Hold
Jefferies
10/31/2024Buy → Neutral
Guggenheim
7/8/2024Buy → Neutral
UBS
6/5/2024$31.00Neutral
Goldman
5/30/2024$47.00Neutral
Goldman
3/4/2024Neutral → Buy
Guggenheim
More analyst ratings

$ARWR
$GSK
$TAK
Press Releases

Fastest customizable press release news feed in the world

See more
  • Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older

    Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years Over half of all women experience a uUTI in their lifetime, with approximately 30% suffering from a recurrent episode Approval based on data from the pivotal phase III EAGLE-2 and EAGLE-3 trials GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and pediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary tract infections (uUTIs) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus

    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

    - ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria - Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24 - Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company's investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025. Selec

    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

    - ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies - Data highlight Arrowhead's leadership in the use of RNA interference to potentially treat Obesity Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weight and fat mass

    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARWR
$GSK
$TAK
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ARWR
$GSK
$TAK
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARWR
$GSK
$TAK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARWR
$GSK
$TAK
Leadership Updates

Live Leadership Updates

See more
  • GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    $AMGN
    $GSK
    $JNJ
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components
  • Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

    NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

    $APO
    $ARWR
    $B
    $GWRE
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

    TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

    $GSK
    $MDCX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARWR
$GSK
$TAK
Financials

Live finance-specific insights

See more
  • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

    − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

    - Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. "During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "The company is now well positioned for

    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

    Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch Products (+14.6% at CER) Core Operating Profit Increase of +10.1% at CER; Core OP Margin Climbs to 28.5% Reported Operating Profit +86.3% at AER Reflects Lower Impairment of Intangible Assets Compared to FY2023 Raises Adjusted Free Cash Flow Forecast Range by JPY 150.0 billion to JPY550.0 - JPY650.0 billion Announces Share Buyback of up to JPY 100.0 billion Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth &

    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARWR
$GSK
$TAK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more